Recent Progress in the Treatment of Acute Lymphoblastic Leukemia, An Issue of Hematology/Oncology Clinics of North America, 1st Edition
Author :
By Wendy Stock, MD and Meir Wetzler, MD
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2
...view more
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Although a few cases are associated with inherited genetic syndromes, the cause of ALL remains largely unknown. This issue presents articles that discuss current thinking on the diagnosis and treatment of the disease. Articles specifically emphasize molecular genetics, allogeneic stem cell transplantation, and treatments including, clofarabine, nelarabine, rituximab, and PegAsp.
Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Although a few cases are associated with inherited genetic syndromes, the cause of ALL remains largely unknown. This issue presents articles that discuss current thinking on the diagnosis and treatment of the disease. Articles specifically emphasize molecular genetics, allogeneic stem cell transplantation, and treatments including, clofarabine, nelarabine, rituximab, and PegAsp.
https://www.asia.elsevierhealth.com/recent-progress-in-the-treatment-of-acute-lymphoblastic-leukemia-an-issue-of-hematologyoncology-clinics-of-north-america-9781437712278.html299570Recent Progress in the Treatment of Acute Lymphoblastic Leukemia, An Issue of Hematology/Oncology Clinics of North Americahttps://www.asia.elsevierhealth.com/media/catalog/product/https://www.asia.elsevierhealth.com/media/catalog/product/placeholder/default/generic_item_image_123x160_1_1.png67.4989.99USDInStock/Clinics/Medicine & Surgery/Hematology/Medicine/Hematology/Clinics/Clinics/Medicine/Hematology/Japan Titles43887254431214505462250546665255041525991152631601418269243350884886536505455351451205259833Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Although a few cases are associated with inherited genetic syndromes, the cause of ALL remains largely unknown. This issue presents articles that discuss current thinking on the diagnosis and treatment of the disease. Articles specifically emphasize molecular genetics, allogeneic stem cell transplantation, and treatments including, clofarabine, nelarabine, rituximab, and PegAsp. Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children, representing nearly one third of all pediatric cancers. The annual incidence of ALL is about 30 cases per million people, with a peak incidence in children aged 2-5 years. Although a few cases are associated with inherited genetic syndromes, the cause of ALL remains largely unknown. This issue presents articles that discuss current thinking on the diagnosis and treatment of the disease. Articles specifically emphasize molecular genetics, allogeneic stem cell transplantation, and treatments including, clofarabine, nelarabine, rituximab, and PegAsp.00add-to-cart97814377122782011 and earlierProfessionalBy Wendy Stock, MD and Meir Wetzler, MD20091Book152w x 229h (6.00" x 9.00")Saunders0Nov 4, 2009IN STOCKBy <STRONG>Wendy Stock</STRONG>, MD and <STRONG>Meir Wetzler</STRONG>, MDClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select
